Jun 14 |
Dow Tumbles Over 200 Points; Adobe Earnings Top Views
|
Jun 14 |
Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
Jun 13 |
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
|
Jun 6 |
MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
|
Jun 4 |
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
|
Jun 3 |
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
|
May 22 |
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
|
May 13 |
Nexalin Technology First Quarter 2024 Earnings: US$0.14 loss per share (vs US$0.10 loss in 1Q 2023)
|
May 9 |
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
|
Apr 25 |
Nexalin Technology regains compliance with Nasdaq continued listing requirements
|